Cargando…

Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2

After the COVID-19 pandemic started all over the world, great importance was placed on the development of sensitive and selective bioanalytical assays for the rapid detection of the highly pathogenic SARS-CoV-2 virus causing COVID-19 disease. In this present work, an impedimetric immunosensor was de...

Descripción completa

Detalles Bibliográficos
Autores principales: Erdem, Arzum, Senturk, Huseyin, Yildiz, Esma, Maral, Meltem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407092/
https://www.ncbi.nlm.nih.gov/pubmed/36010342
http://dx.doi.org/10.3390/diagnostics12081992
_version_ 1784774280027832320
author Erdem, Arzum
Senturk, Huseyin
Yildiz, Esma
Maral, Meltem
author_facet Erdem, Arzum
Senturk, Huseyin
Yildiz, Esma
Maral, Meltem
author_sort Erdem, Arzum
collection PubMed
description After the COVID-19 pandemic started all over the world, great importance was placed on the development of sensitive and selective bioanalytical assays for the rapid detection of the highly pathogenic SARS-CoV-2 virus causing COVID-19 disease. In this present work, an impedimetric immunosensor was developed and applied for rapid, reliable, sensitive and selective detection of the SARS-CoV-2 S1 protein. To detect the SARS-CoV-2 virus, targeting of the spike S1 protein was achieved herein by using S1 protein-specific capture antibody (Cab-S1) immobilized screen-printed electrode (SPE) in combination with the electrochemical impedance spectroscopy (EIS) technique. With the impedimetric immunosensor, the detection limit for S1 protein in buffer medium was found to be 0.23 ng/mL (equal to 23.92 amol in 8 µL sample) in the linear concentration range of S1 protein from 0.5 to 10 ng/mL. In the artificial saliva medium, it was found to be 0.09 ng/mL (equals to 9.36 amol in 8 µL sample) in the linear concentration range of S1 protein between 0.1 and 1 ng/mL. The selectivity of the impedimetric immunosensor toward S1 protein was tested against influenza hemagglutinin antigen (HA) in the buffer medium as well as in artificial saliva.
format Online
Article
Text
id pubmed-9407092
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94070922022-08-26 Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2 Erdem, Arzum Senturk, Huseyin Yildiz, Esma Maral, Meltem Diagnostics (Basel) Article After the COVID-19 pandemic started all over the world, great importance was placed on the development of sensitive and selective bioanalytical assays for the rapid detection of the highly pathogenic SARS-CoV-2 virus causing COVID-19 disease. In this present work, an impedimetric immunosensor was developed and applied for rapid, reliable, sensitive and selective detection of the SARS-CoV-2 S1 protein. To detect the SARS-CoV-2 virus, targeting of the spike S1 protein was achieved herein by using S1 protein-specific capture antibody (Cab-S1) immobilized screen-printed electrode (SPE) in combination with the electrochemical impedance spectroscopy (EIS) technique. With the impedimetric immunosensor, the detection limit for S1 protein in buffer medium was found to be 0.23 ng/mL (equal to 23.92 amol in 8 µL sample) in the linear concentration range of S1 protein from 0.5 to 10 ng/mL. In the artificial saliva medium, it was found to be 0.09 ng/mL (equals to 9.36 amol in 8 µL sample) in the linear concentration range of S1 protein between 0.1 and 1 ng/mL. The selectivity of the impedimetric immunosensor toward S1 protein was tested against influenza hemagglutinin antigen (HA) in the buffer medium as well as in artificial saliva. MDPI 2022-08-17 /pmc/articles/PMC9407092/ /pubmed/36010342 http://dx.doi.org/10.3390/diagnostics12081992 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Erdem, Arzum
Senturk, Huseyin
Yildiz, Esma
Maral, Meltem
Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2
title Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2
title_full Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2
title_fullStr Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2
title_full_unstemmed Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2
title_short Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2
title_sort impedimetric detection based on label-free immunoassay developed for targeting spike s1 protein of sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407092/
https://www.ncbi.nlm.nih.gov/pubmed/36010342
http://dx.doi.org/10.3390/diagnostics12081992
work_keys_str_mv AT erdemarzum impedimetricdetectionbasedonlabelfreeimmunoassaydevelopedfortargetingspikes1proteinofsarscov2
AT senturkhuseyin impedimetricdetectionbasedonlabelfreeimmunoassaydevelopedfortargetingspikes1proteinofsarscov2
AT yildizesma impedimetricdetectionbasedonlabelfreeimmunoassaydevelopedfortargetingspikes1proteinofsarscov2
AT maralmeltem impedimetricdetectionbasedonlabelfreeimmunoassaydevelopedfortargetingspikes1proteinofsarscov2